Australia markets closed
  • ALL ORDS

    6,696.50
    +29.00 (+0.43%)
     
  • AUD/USD

    0.6481
    +0.0023 (+0.35%)
     
  • ASX 200

    6,496.20
    +26.80 (+0.41%)
     
  • OIL

    77.78
    +1.07 (+1.39%)
     
  • GOLD

    1,644.50
    +11.10 (+0.68%)
     
  • BTC-AUD

    31,176.35
    +1,716.26 (+5.83%)
     
  • CMC Crypto 200

    461.31
    +28.21 (+6.51%)
     

Investors in MedAdvisor (ASX:MDR) have unfortunately lost 51% over the last three years

·3-min read

If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough on longer term MedAdvisor Limited (ASX:MDR) shareholders. Regrettably, they have had to cope with a 52% drop in the share price over that period. And over the last year the share price fell 36%, so we doubt many shareholders are delighted. The falls have accelerated recently, with the share price down 48% in the last three months.

It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.

Check out our latest analysis for MedAdvisor

MedAdvisor wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last three years, MedAdvisor saw its revenue grow by 80% per year, compound. That's well above most other pre-profit companies. In contrast, the share price is down 15% compound, over three years - disappointing by most standards. This could mean hype has come out of the stock because the losses are concerning investors. But a share price drop of that magnitude could well signal that the market is overly negative on the stock.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

Take a more thorough look at MedAdvisor's financial health with this free report on its balance sheet.

A Different Perspective

Investors in MedAdvisor had a tough year, with a total loss of 36%, against a market gain of about 5.6%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 2% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that MedAdvisor is showing 4 warning signs in our investment analysis , you should know about...

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.